The NHS Innovation and Technology Payment (ITP) 2019/20 programme went live on 1 April 2019, and builds on the Innovation and Technology Tariff (ITT) and ITP 2018/19.
The ITP aims to remove barriers to the spread and adoption of innovative products or technologies (medical devices, digital platforms and technologies), including financial negotiations.
The programme forms part of a wider set of activities to support innovation in the NHS, led by NHS England in partnership with the AHSN Network.
The innovations offered through the ITP 2019/20 are:
This innovation aims to reduce the side effects for men undergoing radiation treatment for prostate cancer. SpaceOAR is a gel which is injected into the space between the prostate and rectum to increase the space between these two organs by around 1cm. Creating this space makes it less likely that the rectum is exposed to radiation during cancer treatment. Read more here.
This is a handheld, patient-controlled, non-invasive vagus nerve stimulator. It is used for preventing and treating cluster headaches. Read more here.
Placental growth factor (PIGF) based testing
PlGF-based testing can be used with clinical judgement and other diagnostic tests to help diagnose suspected pre-eclampsia. Pre-eclampsia is a condition that affects some pregnant women, usually during the second half of pregnancy. It causes high blood pressure and protein in the urine and, if not diagnosed and closely monitored, it can lead to potentially life-threatening complications. Read more here.
High-sensitivity troponin testing
High sensitivity troponin assays have been developed to detect lower levels of troponin in the blood earlier than older standard assays, leading to improved early detection of acute heart attacks. Read more here.